Telo Therapeutics

Executive Summary

Telo Therapeutics is a preclinical oncology company pioneering the combination of targeted protein degradation (TPD) with nuclear transport inhibition to address cancers resistant to standard therapies. By leveraging the ubiquitin-proteasome system to selectively degrade key oncogenic proteins, Telo aims to overcome the limitations of conventional small-molecule inhibitors, particularly in tumors with aberrant nuclear export or import pathways. The company’s platform centers on developing novel degraders of nuclear transport factors, such as CRM1, which are frequently overexpressed in refractory cancers. This dual mechanism—blocking nuclear export while degrading the target—could lead to more durable responses and a broader therapeutic window. Telo’s approach is designed for patients with limited treatment options, including those with relapsed/refractory hematologic malignancies and solid tumors. As a private, pre-clinical entity founded in 2018 and based in San Francisco, Telo Therapeutics has not yet disclosed total funding or valuation. The company’s current focus is on advancing its lead degrader candidates through IND-enabling studies. While the TPD field has gained significant traction, Telo’s specific niche in nuclear transport degradation differentiates it from competitors like Arvinas or Kymera. The primary near-term risk is technical execution, as the first-in-class mechanism must demonstrate potent degradation and favorable pharmacokinetics. If successful, Telo’s platform could unlock a new class of oncology therapies. The upcoming milestones will be critical in validating the platform and attracting additional capital or partnerships.

Upcoming Catalysts (preview)

• Q4 2026Completion of Lead Optimization for CRM1 Degrader Program70% success
• Q2 2027IND-Enabling Toxicology Studies Initiation60% success
• Q1 2027Series B Financing or Strategic Partnership Announcement50% success